Phone (Direct)
+1 973 ❅❅❅ ❅❅❅❅
Phone (Direct)
Phone (HQ)
+41 613241111
Phone (HQ)
❅❅❅❅❅@ptd.net
Office Address (HQ)
Forum 1 Novartis Campus, Basel, Basel-City, 4056, Switzerland
Office Address (HQ)
Get 10 Free Leads on us
Use our Chrome Extension & instantly connect with prospects
Victoria Kusiak
Novartis
Get Free Access to Victoria’s Contact InfoAccording to Datanyze information, these are Victoria Kusiak's contact details. Reveal the hidden information below for FREE!
Phone (Direct)
+1 973 ❅❅❅ ❅❅❅❅
Phone (Direct)
Phone (HQ)
+41 613241111
Phone (HQ)
❅❅❅❅❅@ptd.net
Office Address (HQ)
Forum 1 Novartis Campus, Basel, Basel-City, 4056, Switzerland
Office Address (HQ)
Victoria Kusiak works as a Executive Vice President & Integrity Chief & Officer at Novartis, which is a Manufacturing company with an estimated 76.1 K employees; and founded in 1996., their management level is C-Level. Victoria graduated from Jacobs Institute for Women's Health and is currently based in New York City, United States. They used to work at U.S. Food & Drug Administration and have used the following emails: , @fda.hhs.gov.
Wow! Victoria seems fun! 😎
Victoria Kusiak's career began less then a year ago. Prior to joining Novartis, Victoria worked at 2 companies.
Deputy Director, Office of Drug Evaluation III
Deputy Director of the Office of Drug Evaluation III In the Center for Drug Evaluation
B. S.
Albright College
M. D.
University of Pennsylvania
MD
Jacobs Institute for Women's Health
Novartis
Forum 1 Novartis Campus, Basel, Basel-City, 4056, Switzerland
76.1 K
$47.7 B
Manufacturing, Pharmaceuticals
Get Full Profile Access
Ice Breakers
Imagine you could know all about Novartis - Victoria Kusiak’s company, before you contact them. Warm up a cold prospect with Datanyze icebreakers
Victoria’s company in the news
Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI
September 24, 2024
Novartis not joining the 'frenzy' of weight loss drugs, CEO says - CNBC
September 18, 2024
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
September 17, 2024
See more
Insights to Break the Ice
In your first interaction
Victoria is located in United States
Work Colleague
See Victoria Kusiak's coworkers out of Novartis's 76.1 K employees